CBTTC Investigator Meeting Washington DC, May 2017

Slides:



Advertisements
Similar presentations
Inhibition of Poly (ADP-Ribose) Polymerase (PARP) by ABT-888 in Patients With Advanced Malignancies: Results of a Phase 0 Trial Shivaani Kummar, MD National.
Advertisements

Ulrik Lassen MD, PH.D Phase 1 Unit
Clinical Implementation of Genomic Cancer Medicine
Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.
Consent for Research Study A study for patients newly diagnosed with advanced glioblastoma (brain cancer): Learning whether a PET scan with F-fluoromisonidazole.
MiRNA-drug resistance mechanisms Summary Hypothesis: The interplay between miRNAs, signaling pathways and epigenetic and genetic alterations are responsible.
What are clinical trials? Phases of Clinical Trials Clinical trials of new medicines are done in phases: Phase I Phase II Phase III.
Precision Medicine: From stratified therapies to personalized therapies Fabrice ANDRE Institut Gustave Roussy Villejuif, France.
Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw, unedited content.
Clinical Trials, TCGA: Deep Integrative Research RT, Imaging, Pathology, “omics” Joel Saltz MD, PhD Director Center for Comprehensive Informatics.
Breast conservation in Locally advanced breast cancer Department of Endocrine Surgery College of Medicine Amrita Institute of Medical Sciences Kochi, Kerala.
Genetic Alterations of TP53 Gene in Brain Astrocytic Tumours Methodology Θ Eighty-three brain tumor biopsies were collected and used in this study. Thirty.
ODAC SCHERING-PLOUGH RESEARCH INSTITUTE 1 Temozolomide Oncology Drug Advisory Committee March 13, 2003 Craig L. Tendler, M.D. Vice President, Oncology.
SARC015: Phase II study of R1507 in wild-type GIST Margaret von Mehren, Fox Chase Cancer Center Katie Janeway, Dana Farber Cancer Institute.
Carol S. Viele RN MS OCN Clinical Nurse Specialist Hematology-Oncology-Bone Marrow Transplant UCSF Associate Clinical; Professor Department of Physiological.
SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.
Consent for Research Study A study for patients newly diagnosed with advanced glioblastoma (brain cancer): Learning whether a PET scan with F-fluoromisonidazole.
Interim Analysis of SARC022, A Phase II study of Linsitinib in Pediatric and Adult Wild Type (WT) Gastrointestinal Stromal Tumors (GIST) M von Mehren,
Initiating phase 1 clinical trials in pediatric oncology National Cancer Institute Perspective Barry Anderson, MD, PhD Pediatric Section Cancer Therapy.
ICNCT-16, June 2014, Helsinki Glioma heterogeneity and the L-Amino acid transporter-1 (LAT1): A first step to stratified BPA-based BNCT? D. Ngoga 1 ; C.
Enrollment and Monitoring Procedures for NCI Supported Clinical Trials Barry Anderson, MD, PhD Cancer Therapy Evaluation Program National Cancer Institute.
C-1 Pegfilgrastim (Neulasta  ) Oncologic Drugs Advisory Committee Pediatric Subcommittee October 20, 2005 Amgen Inc.
Prioritizing New Agents for Pediatric Oncology Evaluation Malcolm A. Smith, MD, PhD Cancer Therapy Evaluation Program National Cancer Institute May 2007.
Full Proposal for the German Cancer Aid Priority Program 'Translational Oncology' (2st call) 2015 Lead Applicants: Prof. Dr. med. Magnus von Knebel Doeberitz.
INTERPRETING GENETIC MUTATIONAL DATA FOR CLINICAL ONCOLOGY Ben Ho Park, M.D., Ph.D. Associate Professor of Oncology Johns Hopkins University May 2014.
Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.
Genomic Medicine Rebecca Tay Oncology Registrar. What is Genomic Medicine? personalised, precision or stratified medicine.
Current Protocols of the Radiation Therapy Oncology Group Montreal, Quebec Nov. 12, 2004.
Precision Medicine Approaches for Children with High Grade Glioma including Diffuse Intrinsic Pontine Glioma 2 nd Annual CBTCC Investigator/Foundation.
Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in.
San Antonio Breast Cancer Symposium – December 6-10, 2016
Emerging Genomic Technologies: Extending the Application of Genomics to Prediction, Diagnosis, Monitoring, and Early Detection Luis A. Diaz, M.D. Johns.
Pichai Raman on behalf of cBioPortal Team Wednesday, May 25, 16
Introduction Review and proper registration of Human Gene Transfer protocols is very complex. A protocol goes through rigorous review by multiple Committees.
Precision Medicine: The Potential for Identifying Personalized Therapies for Patients with Gastro-Esophageal Cancer.
Integrated genomic and proteomic analysis identifies PTEN loss and AKT/MTOR as drivers of resistance to MEK inhibitors in NSCLC cells Dianren Xia1, Lauren.
Harmonizing Bio-informatics with Clinical Reality
Value of Sequencing-Guided Treatment for Patients with
Fig 1A. Patient enrollment flow chart
Pediatric Brain Tumors: The Need for “Pristine” Biologic and Clinical Data Roger J. Packer, MD Senior Vice-President Neuroscience and Behavioral Medicine.
Establishing a Pediatric CNS Biorepository
016 - Comprehensive Molecular Analysis of Pediatric Thalamic Tumors
Jeopardy Testing 1, 2, 3 She Has The Cancer Radiation or Chemo?
NF1 Low-Grade Glioma Synodos
Angela J Waanders, MD, MPH The Children’s Hospital of Philadelphia
Sarah Leary, MD MS CBTTC 5/25/2016
Multiple Myeloma Research Foundation
State of the Science in Autism (on the path to precision medicine)
The Immune System. The Immune System Adaptive Immune Response.
Clinical trial matching.
SWAG SSG Sarcoma Cancer Meeting
Monitoring EGFR mutation status in Non-small cell lung cancer (NSCLC) patients using circulating Tumour DNA (ctDNA). Matthew Smith Molecular Pathology.
Genomic Medicine Centre Overview
SWAG SSG Brain and CNS Cancer Meeting
Adam L. Cohen, MD, MS Assistant Professor Division of Oncology
Protocol Summary National Wilms Tumor Study Group (NWTS)
DKTK MASTER is an example of whole-exome and transcriptome sequencing-based precision oncology programme. DKTK MASTER is an example of whole-exome and.
Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.
All for One: Multidisciplinary Management in EGFR-Mutated NSCLC
CoPrincipal Investigators
PROSTATE CANCER CIRCULATING BIOMARKER CONSENSUS STATEMENT QUESTIONS
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.
MX39795 Study Design Category 1 R 3:1 Category 2 Inclusion criteria
Genomic Medicine Centre Overview
SWAG SSG Brain Cancer Meeting
Presentation and progression of glioblastoma with PNET features in an adult patient. Presentation and progression of glioblastoma with PNET features in.
Overall Survival and Progression-free Survival
One potential implementation for the use of outlier kinase profiling and targeting for clinical management of pancreatic cancer in a precision medicine.
Updates in Best Practices in Non-Small Cell Lung Cancer
DO NOT POST #4054 Gene expression Difference (GED) Revealed Immune Function Gene UP- or Down-regulation as Tumor-associated Inflammatory Cell (TAIC) Infiltration.
Presentation transcript:

CBTTC Investigator Meeting Washington DC, May 2017 PNOC003 A pilot trial testing the clinical benefit of using molecular profiling to determine an individualized treatment plan in children and young adults with newly diagnosed DIPG CBTTC Investigator Meeting Washington DC, May 2017

Precision medicine trial for children with DIPG PK and PD analysis in recurrent sample Child with newly diagnosed DIPG NO Candidate for biopsy / resection YES Patient is eligible Patient is not eligible Biopsy / clinical pathology Evidence of progression / recurrence: Re-consent patient for repeat biopsy NO Adequate sample: > 50% tumor YES Correlative Studies: Xenograft models Circulating tumor cells Whole-genome sequencing Clinical genomics (TGEN): Gene expression profiling Whole-exome sequencing Predictive modeling Off study Report Specialized tumor board issues treatment recommendation Monitor patient for safety and clinical response

PNOC003 Milestones 8/4/2014: Initial Protocol sent to sites 9/16/2014: First patient enrolled 5/11/2016: Protocol v3 sent to sites (feasibility portion completed) – manuscript in preparation

Enrollment Summary Total 31 patients enrolled to date Feasibility portion: enrolled total of 17 subjects: 2 were not eligible due to non eligible tissue diagnosis (astrocytoma grade 1, ETANTR) For one patient RNA seq analysis was unsuccessful 8/14 from feasibility portion followed treatment recommendation: One patient recommendation was single agent panobinostat but this was started already during radiation therapy One patient followed the therapy recommendation however was started late on therapy plan and therefore counted as not following therapy recommendation Several families decided not to pursue any further therapy or enroll into other trials such as CED etc. PNOC003 – astro grade 1 PNOC004 did not follow PNOC005- followed but started late and no communication with PNOC and therefore decision was made to not count as following therapy

DNA and RNA Alterations

Treatment Recommended DNA Level Alterations & Treatment Recommendations Treatment Recommended Etoposide, dasatinib Cabozantinib, etoposide, mebendazole AZD1775 (clinical trial), temozolomide, sertraline Panobinostat, mebendazole (or cabozantinib) Panobinostat, mebendazole Erlotinib, propranolol, everolimus, etoposide Panobinostat, everolimus, sertraline (mebendazole if well-tolerated) Panobinostat, everolimus, mebendazole (or dasatinib) Panobinostat Vemurafenib/dabrafenib, trametinib, minocycline, panobinostat Etoposide, metformin, mebendazole, sertraline Panobinostat, everolimus, mebendazole/cabozantinib, valproic acid Panobinostat, mebendazole, cabozantinib, valproic acid Panobinostat, cabozantinib, valproic acid, mebendazole Panobinostat, mebendazole, propranolol, valproic acid Panobinostat, olaparib, irinotecan Trametinib, everolimus, palbociclib, mebendazole Panobinostat, everolimus, metformin, etoposide Everolimus, trametinib, panobinostat, metformin Panobinostat, mebendazole, etoposide, consider ALK inhibitor Panobinostat, dasatinib, mebendazole Panobinostat, everolimus, propranolol, mebendazole/metformin Panobinostat, mebendazole, sorafenib Panobinostat, everolimus, mebendazole, etoposide (or dasatinib)

Recurrent sample driven by EGFR activation

Correlative Biology 7 cell lines established: PNOC003-04, PNOC003-5,PNOC003-26, SF10423, 10438, 10693, 10864 PNOC003-5, 11 and 26 have been passaged two times. PNOC3-04, SF10693, 10423 and 10844 in vivo have been passaged at least 3x with up to 7 passages; PNOC003-23, PNOC003-29,SF10424,10438, 10475, 10493,10516 and 10864 passaged once. => possible 7-15 new DIPG model systems Analysis of circulating tumor DNA at baseline and with MRI scans (Javad Nazarian) Whole genome analysis and methylation studies of both human samples and associated cell lines/xenografts (Adam Resnick)

Acknowledgements Patient & Families PNOC PIs PNOC OP’s Funding Adam Resnick Javad Nazarian Nalin Gupta Michael Prados Lindsay Kilburn John Kuhn Mike Berens Winnie Liang Sara Byron Mitch Berger Claudia Petritsch Nathalene Truffeaux Xiaodong Yang John Crawford Kellie Nazemi Eugene Huang Brian Hood Suresh Magge Roger Packer Allison Ross David Craig Alison Roos Patient & Families PNOC PIs PNOC OP’s Jenna Weight Lajhem Cambridge Jordana Sandy Annette Molinaro Funding NIH through Cancer Center Award V Foundation Pediatric Brain Tumor Foundation Vs. Cancer Foundation Department of Neurosurgery, UCSF